Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dissapointment

<< Previous

Bullboard Posts

Next >>

Post by Layth1990on Dec 18, 2020 9:35am

169 Views

Post# 32138945

Dissapointment

If RS is not backed up by good news, we will go to hell. i'm really disappointed In this management. i thought they are smarter than this. RS for Nasdaq ? institutional investors? with dilution ? that is Idiotic, this should be before rs. YOU ONLY DO RS WHEN U CAN BACK IT UP WITH GOOD NEWS NOT BURNING IT AND DEFEAT ITS PURPOSE! They burned the sp and will push away investors. Nasdaq already out in near term

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks